Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    17-October-2000      
Issue 187 Next Update - 14:00 UTC 08:00 EST    18-October-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya FDA Meets To Receive Public Testimony On Immune Based Therapies For HIV

Move Surprises HIV/AIDS Activists

Over the past 14 months, AIDS treatment activists, many of whom are members of The HIV Immune Based Therapy Working Group have placed pressure on the Food and Drug Administration regarding the FDA process, procedures and review of immune based therapies for the treatment of HIV disease. In a surprise turn of events by the FDA Antiviral Committee, a meeting took place yesterday to discuss these issues.

The pressure placed on the FDA by AIDS treatment activists over the past 14 months about the review process of immune based therapies including IL-2, made by Chrion, and Ampligen, made by Hemispherx Biopharma came to a head at a controversial meeting, held in Washington DC. The meeting was open to the public, and convened to discuss how the Antiretroviral committee should proceed in its review of these therapeutic options for people with AIDS.

"The FDA has been slow to acknowledge that there is a lack of meritorious review procedures in place to ensure scientifically valid consideration of these clinical options," said Jeannie Gibbs of the IBT Working Group.

The FDA posted a notice (with limited distribution) about the proposed contents of the meeting.

It was hoped by the AIDS treatment activists that the FDA would use the opportunity to begin to catch up with the rest of the clinical community involved in HIV research and allow for some strong determining results that encourage the development of valid clinical research on immune restoration for HIV disease.

Researchers interested in what took place at yesterday's meetings can contact: Nancy Chamberlin, or Beverly O'Neil, Center for Drug Evaluation and Research (HDF-21), Food and Drug Administration, 5600 Fishers Lane, (for express delivery) 5630 Fishers Lane Rm. 1093) Rockville, MD 20857, or by e-mail: CHAMBERLINN@CDER.FDA.GOV.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.